New Program Expands Access to PacBio's
Highly Accurate Sequencing Systems by Providing Flexible Financing
MENLO
PARK, Calif., Sept. 12,
2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a
leading developer of high-quality, highly accurate sequencing
solutions, today announced PacBio Capital, a program that offers
customers the ability to lease PacBio sequencing systems – Revio,
Onso and Sequel IIe – easily and cost-effectively.
"Through PacBio Capital, we can expand our ability to reach
customers and new markets," said Christian
Henry, President and Chief Executive Officer of PacBio. "By
making it possible to lease our game-changing sequencing systems,
customers can conserve capital, and keep monthly payments down
while continuing with their groundbreaking research."
PacBio Capital allows qualified customers to choose capital and
operating lease structures with highly competitive rates and a
six-month same as cash financing option. The streamlined credit and
funding process can enable labs to fast-track their purchase of
PacBio systems and allow more customers to benefit from the
sub-$1,000 HiFi human genome on the
recently released Revio system.
"It's a win/win for PacBio and our current and future
customers," said Jeff Eidel, Chief
Commercial Officer at PacBio. "With PacBio Capital, we aim to get
more systems into the hands of customers faster by offering them
the flexibility to lease our products under the terms that work
best for them."
PacBio has partnered with Mitsubishi HC Capital, a vendor
finance company headquartered in Edina,
Minn. with more than 30 years of experience in this sector
to manage PacBio Capital in the U.S. Additional financing offerings
are available globally through partners including Evosciences. The
program is available now.
About PacBio
PacBio (NASDAQ: PACB) is a premier life
science technology company that is designing, developing and
manufacturing advanced sequencing solutions to help scientists and
clinical researchers resolve genetically complex problems. Our
products and technologies stem from two highly differentiated core
technologies focused on accuracy, quality and completeness which
include our HiFi long-read sequencing and our SBB® short-read
sequencing technologies. Our products address solutions across a
broad set of research applications including human germline
sequencing, plant and animal sciences, infectious disease and
microbiology, oncology, and other emerging applications. For more
information, please visit www.pacb.com and follow @PacBio.
PacBio products are provided for Research Use
Only. Not for use in diagnostic procedures.
Forward-Looking Statements
This press release may
contain "forward-looking statements" within the meaning of Section
21E of the Securities Exchange Act of 1934, as amended, and the
U.S. Private Securities Litigation Reform Act of 1995. All
statements, other than statements of historical fact, are
forward-looking statements, including statements relating to the
uses, accuracy, coverage, advantages, quality or performance of, or
benefits or expected benefits of using, PacBio products or
technologies; ability to reach new customers and markets; plans to
get more systems into customers' hands; and other forward-looking
statements. Readers are cautioned not to place undue reliance on
these forward-looking statements and any such forward-looking
statements are qualified in their entirety by reference to the
following cautionary statements. All forward-looking statements
speak only as of the date of this press release and are based on
current expectations and involve a number of assumptions, risks and
uncertainties that could cause the actual results to differ
materially from such forward-looking statements, including, among
others, potential product performance and quality issues; rapidly
changing technologies and extensive competition in genomic
sequencing that could make the products in development obsolete or
non-competitive; supply chain risks; customers and prospective
customers curtailing or suspending activities utilizing our
products; and third-party claims alleging infringement of patents
and proprietary rights or seeking to invalidate patents or
proprietary rights. Readers are strongly encouraged to read the
full cautionary statements contained in PacBio's filings with the
Securities and Exchange Commission, including the risks set forth
in PacBio's Forms 8-K, 10-K, and 10-Q. PacBio disclaims any
obligation to update or revise any forward-looking statements.
Contacts
Investors:
Todd Friedman
ir@pacificbiosciences.com
Media:
Lizelda Lopez
pr@pacificbiosciences.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/pacbio-announces-pacbio-capital-301923970.html
SOURCE Pacific Biosciences of California, Inc.